Leap Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Gilead Sciences, Inc. has reported a complete divestment of its beneficial ownership in Cypherpunk Technologies Inc., holding 0% of common stock.
Sean Michael Severns filed a Schedule 13G revealing beneficial ownership of 6,000,000 Cypherpunk Technologies shares (10.59%) with sole voting and dispositive power.
Samsara BioCapital, L.P. and its affiliates have reported a complete divestment of their beneficial ownership in Leap Therapeutics, Inc. common stock.
Balyasny Asset Management and its affiliates have filed an amended Schedule 13G, indicating they no longer hold a beneficial ownership stake in Leap Therapeutics, Inc.